Catalysts of change: Immunotherapy's frontier in oral oncology
Oral cancer, which is a kind of HNSCC, presents considerable experimental difficulties because of its high rates of illness and death, often being identified at late stages. Although there have been improvements in conventional treatments such surgery, radiation, and chemotherapy, the outlook for pa...
Saved in:
Main Authors: | Shyamaladevi Babu, Madhan Krishnan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-09-01
|
Series: | Oral Oncology Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024004473 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Drug delivery systems for oral cancer treatment: A patent perspective
by: Mohamed Hassan Dehghan, et al.
Published: (2024-03-01) -
The role of immunotherapy in the treatment of lip squamous cell carcinoma: A series of six cases and a review of the current literature
by: Ido Amir, et al.
Published: (2024-06-01) -
Efficacy and safety of immunotherapy for head and neck squamous cell carcinoma: a meta-analysis of randomized clinical trials
by: Cailing Jiang, et al.
Published: (2025-01-01) -
Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy
by: Madhusudan Roy, et al.
Published: (2024-03-01) -
Clinicopathological risk factors of oral second primary tumours
by: Jelena Karan, et al.
Published: (2024-09-01)